Search results for "DOSAGE FORMS"

showing 10 items of 39 documents

Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Amoxicillin Trihydrate

2018

Literature and experimental data relevant to waiver of in vivo bioequivalence (BE) testing for the approval of immediate-release solid oral dosage forms containing amoxicillin trihydrate are reviewed. Solubility and permeability characteristics according to the Biopharmaceutics Classification System (BCS), therapeutic uses, therapeutic index, excipient interactions, as well as dissolution and BE and bioavailability studies were taken into consideration. Solubility and permeability studies indicate that amoxicillin doses up to 875 mg belong to BCS class I, whereas 1000 mg belongs to BCS class II and doses of more than 1000 mg belong to BCS class IV. Considering all aspects, the biowaiver pro…

0301 basic medicine030106 microbiologyAdministration OralBiological AvailabilityPharmaceutical ScienceExcipientPharmacologyBioequivalence030226 pharmacology & pharmacyPermeabilityDosage formBiopharmaceuticsExcipients03 medical and health sciences0302 clinical medicinemedicineAnimalsHumansDosage FormsActive ingredientChemistryBiopharmaceuticsAmoxicillinAmoxicillinBiopharmaceutics Classification SystemBioavailabilitySolubilityTherapeutic Equivalencymedicine.drugJournal of Pharmaceutical Sciences
researchProduct

Effect of Calcium Ions on the Disintegration of Enteric-Coated Solid Dosage Forms.

2015

To investigate the effect of calcium ions on the disintegration of enteric-coated dosage forms, disintegration testing was performed on enteric-coated aspirin tablets in the presence and absence of calcium in the test media. The results show that the presence of calcium ions retards the disintegration of enteric-coated dosage forms. This finding, which has not been reported in scientific literature, sheds light on the importance of conducting well-designed detailed investigations into the potential of calcium from dietary sources, calcium supplements, antacids, and/or phosphate binders affecting the absorption of drugs formulated into enteric-coated dosage forms. Moreover, it shows the nece…

030213 general clinical medicineDrug LiberationPharmaceutical Sciencechemistry.chemical_elementExcipientCalciumPharmacology030226 pharmacology & pharmacyDosage form03 medical and health scienceschemistry.chemical_compoundCalcium Chloride0302 clinical medicinemedicineSolubilityDosage FormsAspirinPhosphateEnteric coatingBioavailabilityDrug LiberationchemistrySolubilityTablets Enteric-Coatedmedicine.drugNuclear chemistryJournal of pharmaceutical sciences
researchProduct

Buccal drug delivery: what's new and what does the future hold?

2014

The buccal mucosa is the stratified squamous epithelial tissue inside lining of the cheeks. It is a favorable site of drug absorption since the tissue is non-keratinized, relatively immobile and strongly supplied with blood by a dense capillary-vessel network; moreover, it is highly tolerant to allergens, resistant to potentially harmful agents and has a relatively low enzymatic activity. The tissue consents quick onset of effect, offers an easily accessible and generally well-accepted site for drug delivery, is a useful route of administration in patients in an unconscious state (e.g., when swallowing is impaired), and is suitable for retentive dosage forms of administration. Buccal mucosa…

3003Drugmedia_common.quotation_subjectChemistry PharmaceuticalPharmaceutical ScienceDentistryPharmacologyDosage formRoute of administrationDrug Delivery SystemsPharmacokineticsMucositisMedicineAnimalsHumansBuccal dosage formmedia_commonDosage FormsDrug Carriersbusiness.industryLocoregional/systemic treatmentMedicine (all)Mouth MucosaAdministration BuccalTransmucosal deliveryBuccal administrationmedicine.diseaseBioavailabilityPharmaceutical PreparationsSettore CHIM/09 - Farmaceutico Tecnologico ApplicativoDrug deliveryBuccal mucosaDiffusion of InnovationbusinessForecastingTherapeutic delivery
researchProduct

High-Concentration Liquid Prednisolone Formula: Filling a Therapeutic Niche in Severe Acute Attacks of Urticaria and Angioedema.

2015

<b><i>Background/Aims:</i></b> According to current guidelines, the emergency kit for patients with severe urticaria and/or angioedema should include a corticosteroid with a prednisolone-equivalent of 50-100 mg. Since severe dysphagia may occur in anaphylaxis, liquid corticosteroids are advantageous. Presently, only liquid preparations with less than 100 mg prednisolone equivalent are available worldwide. <b><i>Methods:</i></b> We prepared a highly concentrated liquid prednisolone formula for oral administration (1 or 5 mg prednisolone per ml). We observed efficacy and safety of 100 mg or >250 mg liquid oral prednisolone in comparison to in…

AdultMaleAdolescentUrticariaPhysiologymedicine.drug_classmedicine.medical_treatmentPrednisoloneAnti-Inflammatory AgentsAdministration OralDermatologyDosage form030207 dermatology & venereal diseases03 medical and health sciencesYoung Adult0302 clinical medicineOral administrationmedicineHumansAngioedemaAgedPharmacologyHigh concentrationDosage FormsAngioedemabusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseTreatment Outcome030228 respiratory systemIntravenous therapyAnesthesiaPrednisoloneCorticosteroidFemalemedicine.symptombusinessAnaphylaxismedicine.drugSkin pharmacology and physiology
researchProduct

High-dose short-term administration of naringin did not alter talinolol pharmacokinetics in humans.

2015

Naringin is considered the major causative ingredient of the inhibition of intestinal drug uptake by grapefruit juice. Moreover, it is contained in highly dosed nutraceuticals available on the market. A controlled, open, randomized, crossover study was performed in 10 healthy volunteers to investigate the effect of high-dose naringin on the bioavailability of talinolol, a substrate of intestinal organic anion-transporting polypeptide (OATP)-mediated uptake. Following 6-day supplementation with 3 capsules of 350 mg naringin daily, 100mg talinolol were administered orally with 3 capsules of the same dietary supplement (1050 mg naringin) on the seventh day. This test treatment was compared to …

AdultMalefood.ingredientAdrenergic beta-AntagonistsPharmaceutical ScienceOrganic Anion TransportersPharmacologyPolymorphism Single NucleotideDosage formGrapefruit juicePropanolamineschemistry.chemical_compoundFood-Drug InteractionsYoung AdultNutraceuticalfoodPharmacokineticsHumansNaringinDosage FormsCross-Over StudiesDose-Response Relationship DrugChemistryCrossover studyBioavailabilityDietary SupplementsFlavanonesFemaleTalinololCitrus paradisiEuropean journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
researchProduct

Use of long acting injectable aripiprazole before and through pregnancy in bipolar disorder: a case report

2019

Abstract Background Long-acting injectable (LAI) antipsychotics for psychotic disorders provide advantages in treatment compliance, but data on their use in pregnancy are very limited. We present a clinical case of aripiprazole LAI use in pregnancy. Case presentation A 43-year-old woman diagnosed with bipolar disorder, with several relapses due to treatment interruption while trying to conceive. Finally, aripiprazole LAI treatment was planned by mutual agreement between doctor and the patient, who took aripiprazole LAI before and during pregnancy. She gave birth at 40 weeks to a 3500 g baby girl with no congenital malformations, who was healthy at 5 months after delivery. Conclusion As far …

AdultPediatricsmedicine.medical_specialtyTime FactorsBipolar disordermedicine.medical_treatmentvirusesAripiprazoleCase Report030226 pharmacology & pharmacyInjections IntramuscularAntipsychotic03 medical and health sciences0302 clinical medicineimmune system diseasesPregnancylcsh:RA1190-1270medicineHumansPharmacology (medical)Bipolar disorderAntipsychoticlcsh:Toxicology. PoisonsPharmacologyDosage FormsPregnancybusiness.industrylcsh:RM1-950Pregnancy Outcomevirus diseasesCongenital malformationsmedicine.diseasePregnancy ComplicationsLong actinglcsh:Therapeutics. PharmacologyTreatment interruptionLong-acting injectable aripiprazoleAripiprazoleFemaleClinical casebusinessmedicine.drugAntipsychotic AgentsFollow-Up StudiesBMC Pharmacology and Toxicology
researchProduct

Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Moxifloxacin Hydrochloride.

2020

Abstract In this monograph, literature data is reviewed to evaluate the feasibility of waiving in vivo bioequivalence testing and instead applying the Biopharmaceutics Classification System (BCS) based methods to the approval of immediate-release solid oral dosage forms containing moxifloxacin hydrochloride as the sole active pharmaceutical ingredient. To facilitate the feasibility decision, solubility and permeability and dissolution characteristics in the context of the BCS, therapeutic index, therapeutic use, pharmacokinetic parameters, bioequivalence/bioavailability issues, drug-excipient interactions and other relevant data were taken into consideration. Moxifloxacin is a BCS class I d…

Break pointBiowaiverMoxifloxacinPharmaceutical ScienceAdministration OralBiological AvailabilityContext (language use)02 engineering and technologyPharmacologyBioequivalenceMoxifloxacin hydrochloride030226 pharmacology & pharmacyDosage formMoxifloxacin hydrochloridePermeabilityBiopharmaceutics03 medical and health sciences0302 clinical medicineMoxifloxacinMedicinePharmacokineticsTherapeutic indexActive ingredientDosage Formsbusiness.industryBiopharmaceutics Classification System021001 nanoscience & nanotechnologyBiopharmaceutics Classification SystemBioavailabilityPharmacodynamicsSolubilityTherapeutic Equivalency0210 nano-technologybusinessmedicine.drugJournal of pharmaceutical sciences
researchProduct

Toward Biopredictive Dissolution for Enteric Coated Dosage Forms

2016

The aim of this work was to develop a phosphate buffer based dissolution method for enteric-coated formulations with improved biopredictivity for fasted conditions. Two commercially available enteric-coated aspirin products were used as model formulations (Aspirin Protect 300 mg, and Walgreens Aspirin 325 mg). The disintegration performance of these products in a physiological 8 mM pH 6.5 bicarbonate buffer (representing the conditions in the proximal small intestine) was used as a standard to optimize the employed phosphate buffer molarity. To account for the fact that a pH and buffer molarity gradient exists along the small intestine, the introduction of such a gradient was proposed for p…

Chemistry PharmaceuticalCmaxBiological AvailabilityPharmaceutical Science02 engineering and technologyBuffers030226 pharmacology & pharmacyDosage form03 medical and health sciencesFirst pass effect0302 clinical medicineIVIVCCoated Materials BiocompatibleIntestine SmallDrug DiscoverymedicineHumansSolubilityDissolutionDosage FormsChromatographyAspirinGastric emptyingChemistryHydrogen-Ion Concentration021001 nanoscience & nanotechnologyEnteric coatingBicarbonatesDrug LiberationKineticsGastric EmptyingSolubilityArea Under CurveMolecular Medicine0210 nano-technologymedicine.drugMolecular Pharmaceutics
researchProduct

Spectrophotometric estimation of bicalutamide in tablets

2007

A simple, sensitive, rapid, accurate and precise spectrophotometric method has been developed for the estimation of bicalutamide in bulk and pharmaceutical dosage forms. Bicalutamide shows maximum absorbance at 272 nm with molar absorptivity of 2.3399×10(4) l/mol/cm. Beer's law was obeyed in the concentration range of 1.5-18 μg/ml. The limit of detection and limit of quantification were found to be 0.1 and 0.4 μg/ml, respectively. Results of analysis were validated statistically and by recovery studies.

Detection limitChromatographyBicalutamideChemistryShort Communicationtablet dosage formsAnalytical chemistryPharmaceutical ScienceMolar absorptivityDosage formAbsorbanceUltraviolet visible spectroscopyBicalutamidemedicineUV spectroscopymedicine.drugIndian Journal of Pharmaceutical Sciences
researchProduct

Hydroxypropylmethylcellulose films for the ophthalmic delivery of diclofenac sodium

2012

Abstract Objectives The aim of this study was to prepare diclofenac/hydroxypropylmethylcellulose (HPMC) and diclofenac-loaded nanoparticles/HPMC films as potential systems for ocular delivery. Methods Two different concentration of the polymer were used: 1.5 and 2.0% w/v. Chitosan–hyaluronic acid nanoparticles were prepared by the ionotropic gelation technique. Nanoparticles were characterized by transmission electron microscopy, dynamic light scattering, drug encapsulation efficiency and rheological studies. In-vitro drug studies and corneal penetration release studies were carried out. Drug release mechanism was finally evaluated by fitting the Ritger and Peppas equation to data. In addit…

DiclofenacPolymersPharmaceutical ScienceNanoparticleAdministration OphthalmicMethylcellulosePharmacologyPermeabilityDosage formDrug Delivery SystemsHypromellose DerivativesDiclofenacDynamic light scatteringmedicineHyaluronic AcidDosage FormsPharmacologychemistry.chemical_classificationChitosanChemistryAnti-Inflammatory Agents Non-SteroidalDiclofenac SodiumPolymerPermeationHypromellose DerivativesNanoparticlesmedicine.drugNuclear chemistryJournal of Pharmacy and Pharmacology
researchProduct